Dostinex Lawsuit

Awards & recognition
Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

Life-threatening heart valve problems have been reported in a number of patients taking Dostinex (cabergoline). Studies have shown that treatment with Dostinex significantly increases the risk of newly diagnosed cardiac valve regurgitation. If you were administered Dostinex for any length of time, you should consult your physician for testing as soon as possible.

What’s the problem?

Dostinex is part of a class of drugs known as dopamine agonists, which are often used for the management of Parkinson’s disease symptoms. Although Dostinex is prescribed for Parkinson’s disease in Europe, in the United States, it is only approved for treatment of a hormone condition and blood disorder known as hyperprolactinemia. In 2005 alone, Dostinex was prescribed to nearly 90,000 patients nationwide and generated sales of approximately $88 million.

Dostinex Heart Valve Disease

Dostinex-induced heart valve disease is a serious, life-threatening condition characterized by dysfunctional valves that inhibit the proper flow of blood through the heart. As a result, oxygenated blood is unable to efficiently reach other parts of the body. This can lead to complications such as heart failure or even death. Other side effects associated with Dostinex use include (but are not limited to):

  • Pulmonary fibrosis
  • Cardiac valvulopathy
  • Leaky heart valves
  • Damage to the Aortic and Mitral valves
  • Valvular heart disease

Click here to view the New England Journal of Medicine (NEJM) study on valvular heart disease and the use of dopamine agonists for Parkinson’s disease.